Literature DB >> 28273992

ANCA Associated Mononeuritis Multiplex with Overlap in Vasculitic Syndromes.

Ravi Anadure1, Coimbatore Narayanan2, Govindraj Varadraj3, Bevinahalli Nandeesh4.   

Abstract

Mononeuritis multiplex is a common manifestation of many illnesses which includes Hansen's disease and certain types of systemic vasculitis. The Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) is a group of rare diseases which show typical characteristic inflammatory cell infiltration and blood vessel wall necrosis. AAV syndromes include Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA). We describe a patient who presented with mononeuritis multiplex and had features of overlap between EGPA and MPA. The patient was treated with standard regimen of steroids and pulsed cyclophosphamide and she achieved excellent clinical remission.

Entities:  

Keywords:  ANCA Associated Vasculitis; Eosinophilic Granulomatosis with Polyangiitis; Microscopic Polyangiitis

Year:  2017        PMID: 28273992      PMCID: PMC5324437          DOI: 10.7860/JCDR/2017/22252.9149

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  10 in total

1.  The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary.

Authors:  J F Fries; G G Hunder; D A Bloch; B A Michel; W P Arend; L H Calabrese; A S Fauci; R Y Leavitt; J T Lie; R W Lightfoot
Journal:  Arthritis Rheum       Date:  1990-08

Review 2.  The role of biologics in treatment of ANCA-associated vasculitis.

Authors:  Chethana Dharmapalaiah; Richard A Watts
Journal:  Mod Rheumatol       Date:  2011-10-29       Impact factor: 3.023

Review 3.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

Authors:  J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1994-02

4.  Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

Authors:  Lorraine Harper; Matthew D Morgan; Michael Walsh; Peter Hoglund; Kerstin Westman; Oliver Flossmann; Vladimir Tesar; Phillipe Vanhille; Kirsten de Groot; Raashid Luqmani; Luis Felipe Flores-Suarez; Richard Watts; Charles Pusey; Annette Bruchfeld; Niels Rasmussen; Daniel Blockmans; Caroline O Savage; David Jayne
Journal:  Ann Rheum Dis       Date:  2011-11-29       Impact factor: 19.103

Review 5.  Overview of the Pathogenesis of ANCA-Associated Vasculitis.

Authors:  Hong Xiao; Peiqi Hu; Ronald J Falk; J Charles Jennette
Journal:  Kidney Dis (Basel)       Date:  2015-12-03

Review 6.  Microscopic polyangiitis: Clinical presentation.

Authors:  Peter M Villiger; Loïc Guillevin
Journal:  Autoimmun Rev       Date:  2010-07-23       Impact factor: 9.754

7.  Clinical manifestations of granulomatosis with polyangiitis (Wegener's granulomatosis) in the upper respiratory tract seen by otolaryngologists in Japan.

Authors:  Yasuaki Harabuchi; Kan Kishibe; Yuki Komabayashi
Journal:  Clin Exp Nephrol       Date:  2013-02-06       Impact factor: 2.801

8.  Polyangiitis overlap syndrome of granulomatosis with polyangiitis (Wegener's granulomatosis) and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

Authors:  Hironori Uematsu; Shohei Takata; Katsuo Sueishi; Hiromasa Inoue
Journal:  BMJ Case Rep       Date:  2014-02-27

9.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01

Review 10.  Eosinophilic granulomatosis with polyangiitis: an overview.

Authors:  Andrea Gioffredi; Federica Maritati; Elena Oliva; Carlo Buzio
Journal:  Front Immunol       Date:  2014-11-03       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.